KAUST ·
KAUST researchers suggest antibody testing can complement PCR tests to reduce false negatives in COVID-19 diagnosis. PCR tests can produce false negative results. Immunodiagnostic tests could help identify unknowingly spreading the disease. Why it matters: Improving diagnostic accuracy is critical for effective pandemic control and public health management in Saudi Arabia and globally.
KAUST ·
KAUST President announced a mandatory COVID-19 screening program for employees and students from November 1-5. The program aims to provide snapshots of COVID-19 prevalence in the community to inform healthcare demands and future plans. The university targets 5,000 individual swabs in partnership with the Ministry of Health, and participation is crucial for the program's success. Why it matters: This proactive measure enables KAUST to maintain a safe environment and continue reopening the campus, setting an example for managing the pandemic sustainably in the region.
KAUST ·
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
KAUST ·
KAUST Associate Professor Peiying Hong delivered a lecture on using wastewater testing to detect outbreaks earlier. The lecture explains how wastewater testing could lead to faster detection and more effective response to future pandemics. The research was presented at King Abdullah University of Science and Technology. Why it matters: Wastewater epidemiology can provide early warnings for emerging pathogens and improve public health preparedness in the region.
MBZUAI ·
The Russian Immune Diversity Atlas project aims to profile immune cells from people of different ancestries at a multiomics level. The goal is to reconstruct a reference atlas of the healthy immune system and investigate its perturbations in Type II Diabetes (T2D). The project seeks to identify novel mechanisms and genetic/epigenetic markers for early T2D diagnostics, prognosis, and therapy as part of the international Human Cell Atlas. Why it matters: Addressing genetic diversity in biomedical research, particularly in the context of the Human Cell Atlas, is crucial for personalized medicine and ensuring that treatments are effective across diverse populations in the Middle East and globally.
KAUST ·
KAUST professor David Ketcheson uses mathematical modeling to understand COVID-19 transmission. He applies differential equations to explain the progression of SARS-CoV-2, utilizing the SIR model to predict the spread. Ketcheson's analysis suggests that the reproduction number for COVID-19 could be as high as 5, emphasizing the need for social distancing. Why it matters: This highlights the role of mathematical modeling and data analysis in understanding and predicting the spread of infectious diseases, particularly in the context of pandemic response.
KAUST ·
KAUST's Rapid Research Response Team (R3T), including Professor Samir Hamdan, is working to understand and counteract the spread of COVID-19. The team assembled a complete homemade, one-step RT-PCR test, comparable to commercial kits, with a patent-free manufacturing recipe. KAUST R3T is also researching faster, more accurate point-of-care tests, including a CRISPR-based molecular test. Why it matters: This research provides accessible testing solutions and contributes to more effective and rapid detection methods for combating viral spread in the region and globally.
KAUST ·
KAUST is joining universities worldwide to expedite licensing for COVID-19 related technologies. KAUST researchers are focusing on developing rapid diagnostic platforms, genomic analyses, and tools to track the virus's spread, collaborating with Saudi healthcare stakeholders. By signing the AUTM COVID-19 Licensing Guidelines and adopting the COVID-19 Technology Development Framework, KAUST will offer royalty-free, time-limited, non-exclusive licenses during and after the pandemic. Why it matters: This initiative facilitates quicker development and broader access to essential technologies for combating COVID-19 in Saudi Arabia and the Middle East.